Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls

Digestive Diseases and Sciences

Volumn 57, Issue 4, 2012, Pages 1039-1044

  Altunöz, Mustafa Erhan ^a,b   Şenateş, Ebubekir ^a   Yeşil, Atakan ^a   Çalhan, Turan ^c   Övünç, Ayşe Oya Kurdaş ^a  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Sakarya Education and Research Hospital ^*  (Turkey)

^c Umraniye Education and Research Hospital   (Turkey)

Author keywords

Crohn's disease; Hepatitis B vaccine; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DESCENDING COLON; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINE FISTULA; MAJOR CLINICAL STUDY; MALE; PANCOLITIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; REMISSION; SEROLOGY; SEX DIFFERENCE; SINGLE DRUG DOSE; STENOSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; VACCINATION;

ADULT; ANTIBODY FORMATION; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; ILEUM; IMMUNIZATION SCHEDULE; IMMUNOSUPPRESSIVE AGENTS; MALE;

EID: 84864053061     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1980-8     Document Type: Article

References (18)

1. Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920-1925.
2. Lu Y, Jacobson D, Bousvaros A, et al. Immunizations in patients with Inflammatory bowel disease. Inflamm Bowel Dis. 2009;15: 1417-1423.
3. Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 02/18/2011. (Epub ahead of print). doi:10.1002/ibd.21668.
4. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol. 2003;30:1624-1625.
5. Bernal I, Domenech E, Garcia-Planella E, et al. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. Gastroenterol Hepatol. 2003; 26:19-22.
6. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834-1840.
7. WHO Publication. Hepatitis B vaccines: WHO position paper- recommendations. Vaccine. 2009;28:589-590.
8. Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: Assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392-403.
9. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: I mmunization of adults. MMWR Recomm Rep. 2006;55:1-33.
10. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677-692.
11. Chaparro M, Villagrasa JR, Rodri0guez NA, Gisbert JP. Immune response to hepatitis B vaccination in patients with inflammatory bowel disease. Gastroenterology. 2010;S138:S197.
12. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc). 2009;132:331-335 (Abstract only).
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
14. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
15. Gilbert MS, James RS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adoles Health. 1995;16:12-17.
16. Tamer A, Karabay O, Koç NI. The efficiency of two doses hepatitis B vaccination in health care workers for immunoprophylaxis. Turkiye Klinikleri J Med Sci. 2006;26:24-28.
17. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336:296-304.
18. Public Health Agency of Canada. Canadian Immunization Guide. 7th ed. 2006. [PHAC Website]. July 18, 2007. Available at: http://www.phacaspc.gc.ca/ publicat/cig-gci/p03-07-eng.php. Accessed 28 June 2011.